At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular diseases, and cancer.
With multiple Phase 2 and Phase 3 trials ongoing and new INDs expected in 2017 and 2018, we believe that we are poised to make a meaningful difference in the lives of patients with severe and rare diseases who have few or no therapeutic options.
The clinical trials listed below are Acceleron or partner-sponsored trials that are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.
|Drug||Study Phase||Disease||Study ID|
Myelodysplastic Syndromes (MDS)
|Luspatercept||Phase II Extension||MDS||NCT02268383|
|Luspatercept||Phase II Extension||Beta-Thalassemia||NCT02268409|
|Luspatercept||Phase II||Anemia in Lower-Risk MDS||NCT01749514|
|Dalantercept||Phase II||Advanced Renal Cell Carcinoma||NCT01727336|
|ACE-083||Phase II||Facioscapulohumeral Muscular Dystrophy||NCT02927080|
|Acceleron trials listed as recruiting or active on www.clinicaltrials.gov|